Development and medical application of nano-sized MRI contrast agents using protein nanocages
| Project/Area Number |
25750176
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biomedical engineering/Biomaterial science and engineering
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
KAWANO Takahito 九州大学, 先端融合医療レドックスナビ研究拠点, 特任助教 (90526831)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | MRI / 造影剤 / DDS / 画像診断システム / ナノ材料 / 分子イメージング / ナノカプセル |
|---|
| Outline of Final Research Achievements |
Contrast agents with greater specificity and sensitivity are required to improve the diagnosis of cancers using MRI. In this study, small heat shock protein 16.5 (Hsp16.5)-based nanocages conjugated with gadolinium(III)-chelated MRI contrast agents were developed for the diagnosis of cancer. Nanocages with one to four hydrophobic domains were designed to investigate whether template size influences relaxivity. MRI data showed that larger nanocages have higher T1 relaxivities than smaller nanocages as a result of 1) a reduction in molecular tumbling rates caused by an increase in nanocage size and 2) a robust cage structure resulting from the introduction of hydrophobic domains. The introduction of iRGD peptides that specifically target neuropilin-1 enabled the selective binding of nanocages to pancreatic cancer cells. Therefore, this iRGD- modified Hsp16.5 nanocage displays great potential as a highly specific and sensitive MRI contrast agent for the diagnosis of pancreatic cancer.
|
Report
(3 results)
Research Products
(15 results)
